Mountain Valley MD Confirms Major Breakthrough in Solubalizing Ivermectin, Files Patent to Protect Intellectual Property and its Application to Covid-19 Therapy
VANCOUVER, B.C. – November 11, 2020 - Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (FRA:20MP) is pleased to announce that it has confirmed a breakthrough in achieving ivermectin water-solubility, which would enable this award-winning “wonder” drug** to be dosed by injection or inhalation in humans without organic solvents.
The Company believes the implications of this major breakthrough will allow for significantly improved dosing by injection, orally consumed enteric coated capsules, and/or inhalation and, based on a recent ICON* study, offer a potentially significant therapeutic in the fight against COVID-19. The ICON study from October this year confirmed that the use of ivermectin is associated with a lower mortality in hospitalized COVID-19 patients despite being limited to an orally dosed tablet with poor bioavailability, an issue that MVMD believes would be directly addressed with the Company’s breakthrough.
Ivermectin is a well-documented anti parasitic drug being used globally in both veterinary and human medicine and its uses are being broadened to include such applications as an anti-malarial. Billons of world-wide doses annually are utilized in underdeveloped countries to protect most domestic and husbandry animals from parasites including poultry, pigs, cattle and horses. Ivermectin has documented limitations due to its poor solubility in water (.005 mg/ml), thereby requiring the use of toxic organic solvents such as glycerol formal and ethanol, eliminating the possibility of FDA approval for a human injectable form or a more bio-available oral solution.
MVMD scientists, while working on improving the inclusion of ivermectin into the Company’s patented Quicksome™ delivery system, made the discovery of improving ivermectin’s water-solubility by nearly 5,000 times and solves the main limiter of the drug to achieve what they believe will be stronger pharmacokinetics and better overall efficacy. The new discovery only uses excipients that are currently approved by the US Food and Drug Administration (FDA), which the Company believes will enable an unprecedented speed to market based on minimal approval steps required for immediate applications in human and animal dosing.
According to The National Center for Biotechnology Information abstract dated October 7, 2020 (Ivermectin: an award-winning drug with expected antiviral activity against COVID-19**), the potential for ivermectin to be an antiviral agent for COVID-19 and other emerging viral diseases is based on the ability to overcome its property of poor water solubility and consequential low oral bioavailability. Appropriate drug formulations must address the poor water-solubility of ivermectin and the difficulty in delivering the drug to desired target areas, notably the pulmonary environment.
“We believe our ivermectin water-solubility breakthrough will provide the efficacy needed to treat respiratory infections by enabling the drug deposition into the airways and lungs through aerosol formulations and pulmonary delivery,” stated Mike Farber, Director of Life Sciences at Mountain Valley MD. “This breakthrough will also allow ivermectin to be administered to humans via syringe and intravenous therapy, presenting unprecedented options to provide treatment for numerous viruses.”
According to Fior Market Research’s (FMR) Global Ivermectin Medication Market Insights research report***, the COVID-19 virus has been found to impact the lungs of patients directly and cause inflammation to several organs. Ivermectin medication has been used for treatment in various viruses such as RNA, Influenza A, Zika Virus, dengue, yellow fever, equine herpesvirus, new castle and others, which had similar symptoms on the human body as that of COVID-19. It has antiviral effects, which provides relief to slow down the effect of symptoms on the body. With several studies and research conducted on the potential contribution of ivermectin, it has been termed as an inhibitor of the SARS-COV-2 virus. Ivermectin is a potential drug for the treatment of viruses as only a single dose of it affects a 5000-fold reduction of viral RNA.
Additionally, FRM reports*** that a recent study has revealed that the use of ivermectin collectively with doxycycline effects the entry of viral in the body and clears a load of the virus by targeting the functional proteins. In the United States and some other countries, an apparent high success rate of the patients who were given ivermectin medication was found. The recovery duration was also found to be shortened in some cases, along with relief in symptoms.
MVMD’s new patent filings cover all macrocyclic lactone cyclodextrin complexes, including ivermectin and selamectin, which have also been shown to be effective in the treatment of tuberculosis even with limited solubility. The Company believes its breakthrough solubility technology can dramatically enhance the efficacy of both inhaled and injected selamectin or ivermectin providing a novel effective therapeutic for tuberculosis.
According to the World Health Organization****, a total of 1.4 million people died from tuberculosis in 2019 (including 208,000 people with HIV). Worldwide, tuberculosis is one of the top 10 causes of death and the leading cause from a single infectious agent, with an an estimated 10 million people falling ill with tuberculosis worldwide in 2019.
“We believe the extrapolation of Mountain Valley MD’s water-soluble breakthrough across countless viral applications to positively impact human and animal health globally is very significant,” stated Dennis Hancock, President & CEO of Mountain Valley MD. “We believe this will dramatically change the effectiveness and application options for numerous drugs on the market while also supporting the invention of novel drugs that are not limited based on their solubility.”
REFERENCE SOURCES
* ICON - Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease – https://journal.chestnet.org/article/S0012-3692(20)34898-4/fulltext
** October 7, 2020 - Ivermectin: an award-winning drug with expected antiviral activity against COVID-19
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539925/
*** Fior Market Research - Global Ivermectin Medication Market Insights research report
www.fiormarkets.com
**** WHO – Tuberculosis Fact Sheet
https://www.who.int/news-room/fact-sheets/detail/tuberculosis
ABOUT MOUNTAIN VALLEY MD HOLDINGS INC.
Mountain Valley MD is building a world-class biotech and life sciences company organization centred around the implementation of its patented Quicksome™ oral drug formulation and delivery technologies to innovate industry leading products that are sought out globally.
MVMD’s proposition for delivering Quicksome™ formulations that have rapid onset, high bioavailability, low variability and precision dosing is core to the Company’s success across key health and wellness categories. Consistent with its vision towards “Helping People Live Their Best Life”, MVMD applies its Quicksome™ technology to its ground-breaking work for the oral delivery of vaccines and pharmaceutical drugs as well as the development of products for pain management, weight loss, energy, focus, sleep, anxiety, and more.
The Company’s patented Quicksome™ desiccation technology utilizes advanced liposomes and other stabilizing molecules to encapsulate and formulate active ingredients into highly efficient product formats that are consumed orally. The result is a new generation of product formulations that are capable of delivering vaccines, drugs and nutraceuticals into the body faster, with greater impact, efficiency and accuracy.
For more Company information and contact details, visit www.mountainvalleymd.com.
SOURCE: Mountain Valley MD Holdings Inc.
FORWARD-LOOKING INFORMATION DISCLAIMER
Certain statements contained in this news release may constitute forward-looking information. Forward-looking information is often, but not always, identified by the use of words such as "anticipate", "plan", "estimate", "expect", "may", "will", "intend", "should", and similar expressions. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information. The Company's actual results could differ materially from those anticipated in this forward-looking information as a result of regulatory decisions, competitive factors in the industries in which the Company operates, prevailing economic conditions, and other factors, many of which are beyond the control of the Company. The Company is making forward-looking statements, including but not limited to with respect to: the intellectual property being considered a breakthrough; the ability to apply the intellectual property as indicated above; the patentability of the intellectual property; and the effect and implications of the intellectual property and such applicationsf. The Company believes that the expectations reflected in the forward-looking information are reasonable, but no assurance can be given that these expectations will prove to be correct and such forward-looking information should not be unduly relied upon. Any forward-looking information contained in this news release represents the Company's expectations as of the date hereof and is subject to change after such date. The Company disclaims any intention or obligation to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required by applicable securities legislation.
For further information:
Dennis Hancock
President and Chief Executive Officer
Mountain Valley MD Holdings Inc.
Telephone: 647-725-9755
Email: [email protected]
